Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: subject hasbraindefinedassociatedsleep
  Phrases that lowered it: childrenand safetyefficacy andinclusivesafety of
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 1.6% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 24 (lowers risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: 17 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 11.3% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 6 (lowers risk) · Who can join
• Sponsor's past trials: 50 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia NCT00857220 · started 2009 · scored riskier than 14% of active trials completed
• Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder NCT05423717 · started 2022 · scored riskier than 33% of active trials completed
• A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia NCT01277107 · started 2011 · scored riskier than 17% of active trials completed
• Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) NCT05101122 · started 2021 · scored riskier than 13% of active trials completed
• A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension NCT03533114 · started 2018 · scored riskier than 43% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.